Effects of angiotensin II blockade on inflammation‐induced alterations of pharmacokinetics and pharmacodynamics of calcium channel blockers

Abstract

Reduced responses to calcium channel blockers in inflammatory conditions appeared to be due to a reduced amount of target protein that was reversed by the angiotensin II antagonist, valsartan.